T. Rowe Price Associates’s Array Biopharma Inc ARRY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q3 | – | Sell |
-5,417,747
| Closed | -$251M | – | 2577 |
|
|
2019
Q2 | $251M | Sell |
5,417,747
-8,002,987
| -60% | -$225M | 0.04% | 414 |
|
|
2019
Q1 | $327M | Buy |
13,420,734
+5,892,776
| +78% | +$123M | 0.05% | 343 |
|
|
2018
Q4 | $107M | Buy |
7,527,958
+1,376,845
| +22% | +$20.9M | 0.02% | 590 |
|
|
2018
Q3 | $93.5M | Sell |
6,151,113
-470,067
| -7% | -$7.2M | 0.01% | 693 |
|
|
2018
Q2 | $111M | Buy |
6,621,180
+573,664
| +9% | +$9.13M | 0.02% | 630 |
|
|
2018
Q1 | $98.7M | Buy |
6,047,516
+2,465,357
| +69% | +$39.5M | 0.02% | 653 |
|
|
2017
Q4 | $45.9M | Sell |
3,582,159
-82,243
| -2% | -$935K | 0.01% | 898 |
|
|
2017
Q3 | $45.1M | Buy |
3,664,402
+2,410,058
| +192% | +$22.4M | 0.01% | 886 |
|
|
2017
Q2 | $10.5M | Sell |
1,254,344
-1,376,500
| -52% | -$11.3M | ﹤0.01% | 1312 |
|
|
2017
Q1 | $23.5M | Buy |
2,630,844
+75,100
| +3% | +$799K | ﹤0.01% | 1090 |
|
|
2016
Q4 | $22.5M | Buy |
2,555,744
+2,410,572
| +1,660% | +$17.7M | ﹤0.01% | 1100 |
|
|
2016
Q3 | $980K | Buy |
+145,172
| New | +$561K | ﹤0.01% | 1750 |
|
|
2015
Q4 | – | Sell |
-5,142,725
| Closed | -$23.5M | – | 2560 |
|
|
2015
Q3 | $23.5M | Sell |
5,142,725
-2,132,475
| -29% | -$12.6M | 0.01% | 1029 |
|
|
2015
Q2 | $52.5M | Sell |
7,275,200
-332,900
| -4% | -$2.46M | 0.01% | 824 |
|
|
2015
Q1 | $56.1M | Sell |
7,608,100
-1,085,000
| -12% | -$7.72M | 0.01% | 795 |
|
|
2014
Q4 | $41.1M | Sell |
8,693,100
-136,500
| -2% | -$540K | 0.01% | 903 |
|
|
2014
Q3 | $31.5M | Sell |
8,829,600
-44,700
| -0.5% | -$176K | 0.01% | 982 |
|
|
2014
Q2 | $40.5M | Sell |
8,874,300
-95,600
| -1% | -$395K | 0.01% | 928 |
|
|
2014
Q1 | $42.2M | Sell |
8,969,900
-44,400
| -0.5% | -$223K | 0.01% | 907 |
|
|
2013
Q4 | $45.2M | Sell |
9,014,300
-72,700
| -0.8% | -$396K | 0.01% | 875 |
|
|
2013
Q3 | $56.5M | Buy |
9,087,000
+2,540,300
| +39% | +$15.1M | 0.01% | 772 |
|
|
2013
Q2 | $29.7M | Buy |
+6,546,700
| New | +$35.2M | 0.01% | 965 |
|
Other funds holding ARRY
T. Rowe Price Associates's ARRY Position: Q3 2019 in Review
T. Rowe Price Associates sold out of Array Biopharma Inc (ARRY) in Q3 2019, closing a stake of 5,417,747 shares — an estimated $251M sold.
T. Rowe Price Associates first reported a position in ARRY in Q2 2013 and held it in 22 quarters. The position peaked at $327M in Q1 2019. 1 fund tracked by Wall St. Rank holds ARRY as of Q3 2019.
- T. Rowe Price Associates reported no remaining Array Biopharma Inc position as of Q3 2019 after selling out during the quarter.
- T. Rowe Price Associates sold 5,417,747 Array Biopharma Inc shares in Q3 2019, an estimated $251M.
- T. Rowe Price Associates first reported a position in Array Biopharma Inc in Q2 2013 and held it in 22 quarters.
- T. Rowe Price Associates's Array Biopharma Inc position peaked at $327M in Q1 2019.
- 1 fund tracked by Wall St. Rank held Array Biopharma Inc as of Q3 2019.
Based on T. Rowe Price Associates's 13F filing for Q3 2019, filed 14 Nov 2019.